Nivolumab plus ipilimumab and pembrolizumab are the most cost-effective front-line treatment options for patients with newly diagnosed advanced melanoma and unknown BRAF status, according to a study published in JAMA...
Nivolumab plus ipilimumab and pembrolizumab are the most cost-effective front-line treatment options for patients with newly diagnosed advanced melanoma and unknown BRAF status, according to a study published in JAMA...
...